KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Total Liabilities (2016 - 2025)

Teladoc Health (TDOC) has disclosed Total Liabilities for 13 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 27.3% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, down 27.3% year-over-year, with the annual reading at $1.5 billion for FY2025, 27.3% down from the prior year.
  • Total Liabilities hit $1.5 billion in Q4 2025 for Teladoc Health, down from $1.5 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $2.1 billion in Q4 2023 to a low of $57.7 million in Q2 2022.
  • Historically, Total Liabilities has averaged $805.0 million across 5 years, with a median of $232.4 million in 2023.
  • Biggest five-year swings in Total Liabilities: crashed 66.05% in 2024 and later soared 2782.02% in 2025.
  • Year by year, Total Liabilities stood at $94.6 million in 2021, then skyrocketed by 52.01% to $143.8 million in 2022, then skyrocketed by 1336.92% to $2.1 billion in 2023, then decreased by 1.98% to $2.0 billion in 2024, then decreased by 27.3% to $1.5 billion in 2025.
  • Business Quant data shows Total Liabilities for TDOC at $1.5 billion in Q4 2025, $1.5 billion in Q3 2025, and $1.5 billion in Q2 2025.